Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer Lapatinib With Foretinib in HER2+ Metastatic Breast Cancer
Early research finds limited activity with the combination of lapatinib and foretinib for advanced HER2+ breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer Aspirin, NSAIDs and Prospective Risk of HER2+ Breast Cancer
Does aspirin or ibuprofen reduce risk of HER2+ breast cancer?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC Everolimus With Trastuzumab and Paclitaxel for HER2+ MBC
Is the combination of everolimus, trastuzumab, and paclitaxel as safe in Asian patients as it is in the overall population?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase III trial led by researchers at the University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 8, 2017 Category: Cancer & Oncology Source Type: news

Ribociclib Effective in Younger Breast Cancer Patients Too Ribociclib Effective in Younger Breast Cancer Patients Too
In premenopausal women with HR-positive, HER2-negative advanced breast cancer, the CDK4/6 inhibitor plus endocrine therapy dramatically improves progression-free survival compared with endocrine therapy alone.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Biological factors don't fully explain racial disparities for breast cancer type
(UNC Lineberger Comprehensive Cancer Center) The biological features of patients' tumors partially explained a racial disparity for women with hormone receptor-positive, HER2-negative breast cancer, but UNC Lineberger Comprehensive Cancer Center researchers said it didn't explain it completely. The preliminary findings were reported at the 2017 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 7, 2017 Category: International Medicine & Public Health Source Type: news

SABCS: Ribociclib Ups PFS in HR + HER2 − Advanced Breast Cancer
Significant improvement in progression - free survival for pre - and perimenopausal women (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pathology, Pharmacy, Conference News, Source Type: news

Trastuzumab No Benefit In Low-HER2 Breast Cancer (CME/CE)
(MedPage Today) -- New findings should ditch use of drug for women not clearly HER2-positive (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 6, 2017 Category: Surgery Source Type: news

No Trastuzumab Benefit in HER2-Low Breast Cancer After All No Trastuzumab Benefit in HER2-Low Breast Cancer After All
Despite previous analyses suggesting that adding trastuzumab to adjuvant chemotherapy may benefit patients with low HER2 expression, a new large trial shows no impact on outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ
Malignant tumors reprogram cellular metabolism to support cancer cell proliferation and survival. Although most cancers depend on a high rate of aerobic glycolysis, many cancer cells also display addiction to glutamine. Glutamine transporters and glutaminase activity are critical for glutamine metabolism in tumor cells. We found that the receptor tyrosine kinase EphA2 activated the TEAD family transcriptional coactivators YAP and TAZ (YAP/TAZ), likely in a ligand-independent manner, to promote glutamine metabolism in cells and mouse models of HER2-positive breast cancer. Overexpression of EphA2 induced the nuclear accumula...
Source: Signal Transduction Knowledge Environment - December 5, 2017 Category: Science Authors: Edwards, D. N., Ngwa, V. M., Wang, S., Shiuan, E., Brantley-Sieders, D. M., Kim, L. C., Reynolds, A. B., Chen, J. Tags: STKE Research Articles Source Type: news

FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer FDA Approves Biosimilar Trastuzumab for HER+ Breast Cancer
The agency has approved the first biosimilar that corresponds to Herceptin for use in HER2+ breast and metastatic stomach cancer.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 1, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Trastuzumab Biosimilar
(MedPage Today) -- Includes HER2-positive breast, stomach cancer (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 1, 2017 Category: Gastroenterology Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
Ogivri, a biosimilar to the cancer drug Herceptin, is approved for HER2+ breast cancer and metastatic stomach cancers SILVER SPRING, Md., Dec. 1, 2017 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today approved Ogiv... Biopharmaceuticals, Oncology, FDA Mylan, Ogivri, trastuzumab-dkst, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 1, 2017 Category: Pharmaceuticals Source Type: news

FDA approves first biosimilar for the treatment of certain breast and stomach cancers
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer. (Source: World Pharma News)
Source: World Pharma News - December 1, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

What's Hot at SABCS 2017? What's Hot at SABCS 2017?
Can the duration of adjuvant therapy in breast cancer be reduced? Is trastuzumab effective in HER2-negative tumors? These are among the hot topics that will be discussed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neratinib: Extended Adjuvant Therapy, But When to Prescribe? Neratinib: Extended Adjuvant Therapy, But When to Prescribe?
The ExteNET study led to the approval of neratinib for extended adjuvant treatment of early-stage HER2+ breast cancer. But when should it be prescribed?Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Negligible Benefit Of Nerlynx, A New Breast Cancer Drug, Calls For Caution
The question for patients with early-stage HER2+ breast cancer is if it ’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 17, 2017 Category: Pharmaceuticals Authors: Elaine Schattner, Contributor Tags: NASDAQ:PBYI VTX:ROG Source Type: news

More than 1,300 women to get breakthrough cancer drug
The treatment – for the aggressive HER2+ form of the disease – extends life for women dying with breast cancer by an average 56 months, 16 months more than the next best treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - November 10, 2017 Category: Consumer Health News Source Type: news

FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic settings. (Source: World Pharma News)
Source: World Pharma News - October 18, 2017 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio ™ (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced or metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - October 13, 2017 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for metastatic breast cancers
The U.S. Food and Drug Administration Thursday approved Verzenio to treat adult patients with HR positive and HER2 negative metastatic breast cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - September 29, 2017 Category: Consumer Health News Source Type: news

Roche's Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Media News)
Source: Roche Media News - September 29, 2017 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review for Roche ’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC). The FDA is exp ected to make a decision on approval by 28 January 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - September 29, 2017 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for certain advanced or metastatic breast cancers
The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient ’s hormones (endocrine therapy). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2017 Category: American Health Source Type: news

FDA Approves Verzeniov (abemaciclib) for Certain Advanced or Metastatic Breast Cancers
September 28, 2017 -- The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Approves Verzenio (abemaciclib) for Certain Advanced or Metastatic Breast Cancers
September 28, 2017 -- The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2017 Category: Drugs & Pharmacology Source Type: news

US Oncology Research Plays an Important Role in the Clinical Development for NERLYNX ™ (Neratinib) Tablets
The Woodlands, Texas (September 12, 2017) — Early-stage breast cancer patients with HER2-positive tumors now have a promising new anti-HER2 treatment option in the extended adjuvant setting, thanks in large part to the efforts and expertise of US Oncology Research and McKesson Specialty Health. US O... (Source: McKesson News)
Source: McKesson News - September 12, 2017 Category: Information Technology Source Type: news

Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer Abemaciclib: First-Line CDK4/6 Inhibitor for Breast Cancer
Abemaciclib, the third CDK4/6 inhibitor, in combination with endocrine therapy shows significant benefit for the first-line treatment of HR+ HER2- advanced breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncolytics Biotech(R) Announces the Presentation of REOLYSIN(R) Clinical Data at ESMO 2017 Congress
Additional randomized phase 2 data in metastatic breast cancer demonstrates doubling of overall survival in Hormone Receptor Positive (ER+PR+)/HER2- patients Largest immuno-oncolytic virus safety database reported to-date demonstrates REOLYSIN® is s... Biopharmaceuticals, Oncology Oncolytics Biotech, REOLYSIN, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 11, 2017 Category: Pharmaceuticals Source Type: news

Taselisib Added to Letrozole Boosts Response in Breast Cancer Taselisib Added to Letrozole Boosts Response in Breast Cancer
Taselisib, a PIK3CA targeted agent, in combination with letrozole significantly increased overall response rates in postmenopausal women with ER+/HER2- stage I-III operable breast cancer. ORRs were more robust in patients with PIK3CA mutations.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity THOUSAND OAKS, Calif. and DUBLIN, Sept. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced data from a Phase 3 study evaluating the efficacy and safety of ABP 980, a Herceptin® (trastuzumab) biosimilar, compared with the originator product in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer. Results from the neoadjuvant efficacy phase of the study, including pathologic complete response ass...
Source: Amgen News Release - September 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

LORELEI: Taselisib boosts breast tumor shrinkage
(European Society for Medical Oncology) Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2017 Category: International Medicine & Public Health Source Type: news

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Breakthrough Therapy designation received for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-D... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, Breakthrough Therapy, DS-8201, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2017 Category: Pharmaceuticals Source Type: news

Daiichi Sankyo and BMS to perform Phase Ib oncology combination trial
Daiichi Sankyo has entered a research collaboration to assess its investigational antibody drug conjugate (ADC) DS-8201 in combination with Bristol-Myers Squibb ’s (BMS) Opdivo (nivolumab) in a Phase Ib clinical trial to treat HER2-expressing metastat… (Source: Drug Development Technology)
Source: Drug Development Technology - August 29, 2017 Category: Pharmaceuticals Source Type: news

Faslodex (fulvestrant) Receives FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer
August 28, 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Cynvenio Launches Newest LiquidBiopsy HER2 Expression Test
High sensitivity blood test allows measurement of HER2 over-expression in patients after primary tumor has been removed and tissue biopsy is no longer available - provides novel way to monitor...(PRWeb August 24, 2017)Read the full story at http://www.prweb.com/releases/2017/08/prweb14631277.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 24, 2017 Category: Pharmaceuticals Source Type: news

Nerlynx (neratinib) for the Treatment of Breast Cancer
Nerlynx ™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early-stage HER2-overexpressed or amplified breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news

Alliance Foundation Trials opens global trial investigating first-in-class palbociclib in HR+, HER2+ metastatic breast cancer
The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, have announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE®). (Source: World Pharma News)
Source: World Pharma News - August 23, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Pyrotinib Promising in Phase I Metastatic HER2-Positive Breast Cancer Trial
A novel ErbB inhibitor called pyrotinib was well tolerated and showed promising activity in patients with metastatic HER2-positive breast cancer, according to results of a phase I trial. (Source: CancerNetwork)
Source: CancerNetwork - August 23, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Pfizer and AFT initiate Phase III trial of HER2+ breast cancer drug
Pfizer and the Alliance Foundation Trials have partnered with six international cancer research groups to initiate a Phase III clinical trial (PATINA) of palbociclib (IBRANCE) in patients with hormone receptor-positive (HR+), human epidermal growth f … (Source: Drug Development Technology)
Source: Drug Development Technology - August 23, 2017 Category: Pharmaceuticals Source Type: news

Clinical Laboratories May Need to Expand Test Portfolios with Companion and Complementary Diagnostic Assays as More Test-Dependent Drug Therapies Enter Market
However, the distinction between how the two different types of diagnostic tests are intended to be used still confuses many physicians and healthcare professionals Companion diagnostics are well-known to medical laboratorians. However, the new-breed of complementary diagnostics might not be as familiar. As the pharmaceutical pipeline increasingly becomes filled with test-dependent new drug therapies, medical […] (Source: Dark Daily)
Source: Dark Daily - August 21, 2017 Category: Laboratory Medicine Authors: Jude Tags: Instruments & Equipment Laboratory Management and Operations Laboratory News Laboratory Operations Laboratory Pathology Laboratory Testing anatomic pathology ANGLE Plc anti-HER2 Brandwidth Solutions Christopher Fikry MD clinical labo Source Type: news

Could Cytotoxic TILs Guide Treatment in Metastatic HER2+ Breast Cancer?
Low levels of cytotoxic stromal tumor-infiltrating lymphocytes are predictive of benefit derived from antibody- vs small molecule –based drug approaches to HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Medical News Today: New compound boosts treatment for aggressive breast cancer
A new anticancer agent, if given in combination with existing treatment, proves highly effective against triple negative and HER2 positive breast cancers. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 3, 2017 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Targeting 'Achilles' heel' could supercharge breast cancer treatment
(Walter and Eliza Hall Institute) A new class of anti-cancer agents targeting cancer cells' 'Achilles' heel' could help to supercharge breast cancer treatment, improving outcomes for the most aggressive types of breast cancer.Combining anti-cancer compound S63845 with currently used cancer drugs was more effective in killing triple negative breast cancers and HER2-positive breast cancers.This is the first time the S63845 compound has been shown to be effective in breast cancer, suggesting it should be investigated in clinical trials. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2017 Category: Cancer & Oncology Source Type: news

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer
There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches. (Source: World Pharma News)
Source: World Pharma News - August 1, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer
(Baylor College of Medicine) A phase II clinical trial of neratinib in patients with metastatic breast cancer carrying a HER2 mutation produces encouraging results in that about 30 percent of patients and a promising diagnostic tool for metastatic breast cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2017 Category: International Medicine & Public Health Source Type: news

Amgen and Allergan Submit Biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer THOUSAND OAKS, Calif., July 31, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AM... Biopharmaceuticals, Generics, Oncology, FDA Amgen, Allergan, ABP 980, Herceptin, (trastuzumab, Genentech, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 31, 2017 Category: Pharmaceuticals Source Type: news

Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer THOUSAND OAKS, Calif., July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 980, a biosimilar candidate to Herceptin® (trastuzumab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is the second to be submitted for FDA approval. "The submission of AB...
Source: Amgen News Release - July 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news